Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Therapeutics and Clinical Risk Management
Volume 19, 2023 - Issue
REVIEW
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Dimitrios D Raptis1 First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece;2 Second Department of Internal Medicine, 424 General Military Hospital, Thessaloniki, Greece
https://orcid.org/0000-0002-2348-7312View further author information
https://orcid.org/0000-0002-2348-7312View further author information, Christos S Mantzoros3 Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;4 Department of Internal Medicine, Boston VA Healthcare System, Harvard Medical School, Boston, MA, 02115, USAhttps://orcid.org/0000-0003-3755-8158View further author information
https://orcid.org/0000-0003-3755-8158View further author information & Stergios A Polyzos1 First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceCorrespondence[email protected]
https://orcid.org/0000-0001-9232-4042View further author information
https://orcid.org/0000-0001-9232-4042View further author information